Aspen annouces deal with Johnson & Johnson to manufacture investigational Covid-19 vaccine candidate

Aspen is working with Johnson & Johnson, for the proposed commercial manufacture of their COVID-19 vaccine candidate, Ad26.COV2-S. The vaccine candidate is currently undergoing clinical trials. Aspen Pharmacare has agreed to provide the necessary capacity required for the manufacture of Johnson & Johnson’s COVID-19 vaccine candidate at its existing sterile facility in Port Elizabeth, South Africa.